August 2020 Vol 11, No 8
Have you ever attended a cyber conference? Think a virtual experience can’t compare to the real thing? Well, many AONN+ members attended our Midyear Virtual Conference this past May, myself included. I have to say, it was an amazing, engaging, and rewarding experience. But don’t just take my word for it. We polled attendees after the 2020 Midyear Virtual Conference. Here are some of the results.
The Oncology Nurse Navigator as “Gate Opener” to Interdisciplinary Supportive and Palliative Care for People with Head and Neck Cancer
Sarah H. Kagan, PhD, RN, AOCN, GCNS-BC, FAAN, FGSA, Brianna Morgan, MSN, CRNP, ACHPN, Teresa Smink, MSN, RN, OCN, Debra DeMille, MS, RD, CSO, Christine Huntzinger, DPT, CCCE, CCI, Meredith Pauly, MA, CCC-SLP, Mary Pat Lynch, MSN, RN, AOCN
An innovative approach to elevate the patient experience and improve clinical outcomes through interdisciplinary supportive and palliative care
Improve your smoking cessation program – click here to learn how.
Vaping devices, also known as e-cigarettes, are the new epidemic among young people in the United States, according to Nancy Sayegh-Rooney, RN, a lung nurse navigator on Staten Island, NY, and a Certified Tobacco Treatment Specialist who educates students in middle school and high school about the dangers of vaping.
Ongoing research and new treatments are giving renewed hope to patients with a triple-negative breast cancer diagnosis.
Bortezomib, Lenalidomide, and Dexamethasone Regimen Remains Standard of Care for Newly Diagnosed Multiple Myeloma
The combination of carfilzomib with lenalidomide and dexamethasone (KRd) as induction therapy has failed to improve outcomes in newly diagnosed multiple myeloma compared with bortezomib, lenalidomide, and dexamethasone (VRd).
Cellular therapy is quickly becoming an attractive option for heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). According to data presented at the ASCO20 Virtual Scientific Program, a pair of chimeric antigen receptor (CAR) T-cell products have generated impressive rates of response that appear to be sustainable as well.
A biosimilar is a “highly similar” copy of a biologic drug, but it is not a generic. This definition understandably causes confusion among oncology patients and providers alike, but it is an important distinction, according to Jim Koeller, MS, professor at The University of Texas at Austin.
KRAS-mutant tumors are notoriously difficult to treat. Early data presented at the 2020 virtual meeting of the American Association for Cancer Research suggest 2 new routes to treating KRAS-mutated cancers: (1) the combination of a RAF/MEK inhibitor and a FAK inhibitor, and (2) onvansertib, a competitive inhibitor of the PLK1 enzyme, together with chemotherapy.
Two studies presented at the 2020 virtual meeting of the American Association for Cancer Research confirm the value of liquid biopsy in the early detection of cancer.
Results 1 - 11 of 11